FOLH1 and neoplasm: Since the simple replacement of HBED-CC in PSMA-11 by DOTA resulted in a significant decrease of the tumour targeting properties, systematic linker alterations were carried out to improve the interaction of the inhibitor with the binding funnel of PSMA [95].